Adagene partners with Incyte for cancer drug combination study
Go back to Adagene partners with Incyte for cancer drug combination study| (NASDAQ: ADAG) | Delayed: 3.64 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.64 | 52 Week High | $ | |||
| Open | $3.60 | 52 Week Low | $ | |||
| Day High | $3.74 | P/E | N/A | |||
| Day Low | $3.60 | EPS | $ | |||
| Volume | 34,954 | |||||
| Incyte Genomics, Inc. (NASDAQ: INCY) | Delayed: 126.25 +1.24 (0.99%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $125.01 | 52 Week High | $118.49 | |||
| Open | $126.43 | 52 Week Low | $55.00 | |||
| Day High | $129.19 | P/E | N/A | |||
| Day Low | $125.89 | EPS | $-0.56 | |||
| Volume | 534,863 | |||||
